<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569942</url>
  </required_header>
  <id_info>
    <org_study_id>ANZIC-RC/SP002</org_study_id>
    <nct_id>NCT04569942</nct_id>
  </id_info>
  <brief_title>Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis</brief_title>
  <acronym>ARISE FLUIDS</acronym>
  <official_title>Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Australian and New Zealand Intensive Care Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic&#xD;
      shock to the emergency department (ED) of participating hospitals in Australia and New&#xD;
      Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids&#xD;
      and early vasopressor regimen or a larger initial IV fluid volume with later introduction of&#xD;
      vasopressors if required. Clinical care including the type of resuscitation fluid and&#xD;
      vasopressor agent, will otherwise be in accordance with accepted standard care and according&#xD;
      to clinician discretion. The study intervention will be delivered for at least 6 hours and up&#xD;
      to 24 hours post-randomisation. Participants will be followed for up to 12 months and&#xD;
      outcomes analysed on an intention-to-treat basis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ARISE FLUIDS study is a multicentre, randomised, parallel group clinical trial of a&#xD;
      restricted fluids and early vasopressor strategy compared to a larger initial IV fluid volume&#xD;
      and later vasopressors for the haemodynamic resuscitation of patients with septic shock&#xD;
      presenting to the ED. It will be conducted in hospitals in Australia and New Zealand with&#xD;
      1000 patients recruited over a 3-year period.&#xD;
&#xD;
      Each patient meeting all of the inclusion and none of the exclusion criteria will be&#xD;
      randomised to receive haemodynamic resuscitation using either a restricted fluid and early&#xD;
      vasopressor regimen (vasopressors arm) or a larger initial fluid resuscitation volume (fluids&#xD;
      arm) followed by later introduction of vasopressors (if required). The intervention will be&#xD;
      commenced in the ED and delivered for at least 6 hours, and up to 24 hours post-randomisation&#xD;
      if admitted to the ICU or other critical care area where the study protocol can be faithfully&#xD;
      delivered. Treatment will revert to usual care as determined by the treating clinician when&#xD;
      the patient is transferred to a non-critical care ward. All enrolled participants will be&#xD;
      followed up and assessed for the defined study outcomes.&#xD;
&#xD;
      Participants will be identified using a systematic approach to screening and assessment of&#xD;
      patients with possible sepsis presenting to the ED in accordance with standard clinical&#xD;
      practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>the number of days alive and out of hospital at 90 days post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization until death</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Time from randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and at home</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Days alive and at home at 90 days post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days to day 28</measure>
    <time_frame>From randomisation until 28 days post- randomization</time_frame>
    <description>Number of days not on invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days to day 28</measure>
    <time_frame>From randomisation until 28 days post- randomization</time_frame>
    <description>Number of days not on vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy-free days to day 28</measure>
    <time_frame>From randomisation until 28 days post- randomization</time_frame>
    <description>Number of days not on renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or disability at 6 months</measure>
    <time_frame>at 6 months post randomization</time_frame>
    <description>Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or disability at 12 months</measure>
    <time_frame>at 12 months post randomization</time_frame>
    <description>Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of invasive mechanical ventilation</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Incidence of invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of invasive mechanical ventilation</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Duration of invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of acute renal replacement therapy</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Incidence of acute renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of acute renal replacement therapy</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Duration of acute renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of vasopressor support</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Incidence of vasopressor support</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of vasopressor support</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Duration of vasopressor support</description>
  </other_outcome>
  <other_outcome>
    <measure>Emergency Department length of stay</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Emergency Department length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Intensive care unit length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Hospital length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>From randomisation until 90 days post- randomization</time_frame>
    <description>Patients who die in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality at 6 months</measure>
    <time_frame>6 Months post- randomization</time_frame>
    <description>mortality at 6 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality at 12 months</measure>
    <time_frame>1 year post- randomization</time_frame>
    <description>mortality at 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life at 6 months</measure>
    <time_frame>6 months post- randomization</time_frame>
    <description>Patient quality of life as measured by the EuroQol Group 5 dimensions 5 levels survey (EQ-5D-5L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life at 12 months</measure>
    <time_frame>1 year post- randomization</time_frame>
    <description>Patient quality of life as measured by the EuroQol Group 5 dimensions 5 levels survey (EQ-5D-5L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness measured as cost/quality-adjusted life year (QALY)</measure>
    <time_frame>1 year post- randomization</time_frame>
    <description>cost effectiveness measured as cost per quality-adjusted life year</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>Vasopressor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a restricted fluids and early vasopressor strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a larger intravenous (IV) fluid volume and later vasopressor strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressor</intervention_name>
    <description>Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.</description>
    <arm_group_label>Vasopressor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluids</intervention_name>
    <description>An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.</description>
    <arm_group_label>Fluids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically suspected infection;&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt;90 mm Hg or mean arterial pressure (MAP) &lt;65 mm Hg,&#xD;
             despite a â©¾1000ml cumulative total bolus of IV fluid administered over a maximum of 60&#xD;
             minutes; including pre-hospital boluses;&#xD;
&#xD;
          -  Arterial or venous blood lactate &gt;2.0 mmol/L;&#xD;
&#xD;
          -  At least one dose of an intravenous antimicrobial has been commenced.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years;&#xD;
&#xD;
          -  Confirmed or suspected pregnancy;&#xD;
&#xD;
          -  Transferred from another acute care facility;&#xD;
&#xD;
          -  Hypotension suspected to be due to a non-sepsis cause;&#xD;
&#xD;
          -  &gt;2L total IV fluid administered (including prehospital fluids but excluding drugs and&#xD;
             flushes);&#xD;
&#xD;
          -  More than 6 hours has elapsed since presentation to the ED or more than 2 hours has&#xD;
             elapsed since last inclusion criterion has been met;&#xD;
&#xD;
          -  Treating clinician considers that one or both of the treatment regimens are not&#xD;
             suitable for the patient or the study protocol cannot be delivered e.g. limitation of&#xD;
             care, requirement for immediate surgery;&#xD;
&#xD;
          -  Death is considered imminent or inevitable;&#xD;
&#xD;
          -  Underlying disease that makes survival to 90 days unlikely;&#xD;
&#xD;
          -  Inability to follow patient up to day-90 e.g. unstable accommodation, overseas&#xD;
             visitor;&#xD;
&#xD;
          -  Previously enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal North Shore Hosptial</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>vasopressor</keyword>
  <keyword>Resuscitation Fluids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

